Encorafenib plus cetuximab for previously treated BRAF V600E mutation-positive metastatic colorectal cancer – final appraisal determination

In this revised DRAFT guidance, following feedback from consultation, encorafenib plus cetuximab is recommended as an option for treating BRAF V600E mutation-positive metastatic colorectal cancer in adults who have had previous systemic treatment.

Source:

National Institute for Health and Care Excellence